Logo image of PACS

PACS GROUP INC (PACS) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:PACS - US69380Q1076 - Common Stock

42.13 USD
+0.62 (+1.49%)
Last: 1/13/2026, 8:04:00 PM
42.91 USD
+0.78 (+1.85%)
After Hours: 1/13/2026, 8:04:00 PM
Fundamental Rating

3

Taking everything into account, PACS scores 3 out of 10 in our fundamental rating. PACS was compared to 100 industry peers in the Health Care Providers & Services industry. PACS may be in some trouble as it scores bad on both profitability and health. PACS shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • PACS had positive earnings in the past year.
PACS Yearly Net Income VS EBIT VS OCF VS FCFPACS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 100M 200M 300M

1.2 Ratios

  • With a Return On Assets value of 0.99%, PACS perfoms like the industry average, outperforming 52.00% of the companies in the same industry.
  • The Return On Equity of PACS (6.40%) is better than 62.00% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 1.75%, PACS is in line with its industry, outperforming 43.00% of the companies in the same industry.
  • PACS had an Average Return On Invested Capital over the past 3 years of 4.48%. This is below the industry average of 9.19%.
Industry RankSector Rank
ROA 0.99%
ROE 6.4%
ROIC 1.75%
ROA(3y)3.46%
ROA(5y)N/A
ROE(3y)120.58%
ROE(5y)N/A
ROIC(3y)4.48%
ROIC(5y)N/A
PACS Yearly ROA, ROE, ROICPACS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 50 100 150 200

1.3 Margins

  • The Profit Margin of PACS (1.36%) is comparable to the rest of the industry.
  • PACS's Profit Margin has declined in the last couple of years.
  • PACS has a Operating Margin (3.01%) which is in line with its industry peers.
  • PACS's Operating Margin has declined in the last couple of years.
  • PACS has a Gross Margin (19.38%) which is in line with its industry peers.
  • PACS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 3.01%
PM (TTM) 1.36%
GM 19.38%
OM growth 3Y-25.04%
OM growth 5YN/A
PM growth 3Y-30.78%
PM growth 5YN/A
GM growth 3Y-5.21%
GM growth 5YN/A
PACS Yearly Profit, Operating, Gross MarginsPACS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 5 10 15 20

More info and screens

1

2. Health

2.1 Basic Checks

  • PACS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, PACS has more shares outstanding
  • PACS has a better debt/assets ratio than last year.
PACS Yearly Shares OutstandingPACS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 50M 100M 150M
PACS Yearly Total Debt VS Total AssetsPACS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

  • PACS has an Altman-Z score of 1.68. This is a bad value and indicates that PACS is not financially healthy and even has some risk of bankruptcy.
  • PACS's Altman-Z score of 1.68 is on the low side compared to the rest of the industry. PACS is outperformed by 61.00% of its industry peers.
  • A Debt/Equity ratio of 0.43 indicates that PACS is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.43, PACS is in the better half of the industry, outperforming 64.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Altman-Z 1.68
ROIC/WACC0.2
WACC8.83%
PACS Yearly LT Debt VS Equity VS FCFPACS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • PACS has a Current Ratio of 0.94. This is a bad value and indicates that PACS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.94, PACS is doing worse than 75.00% of the companies in the same industry.
  • PACS has a Quick Ratio of 0.94. This is a bad value and indicates that PACS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • PACS has a worse Quick ratio (0.94) than 70.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.94
Quick Ratio 0.94
PACS Yearly Current Assets VS Current LiabilitesPACS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 200M 400M 600M 800M

More info and screens

7

3. Growth

3.1 Past

  • PACS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -50.86%.
  • PACS shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.97% yearly.
  • The Revenue has grown by 31.44% in the past year. This is a very strong growth!
  • PACS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 51.91% yearly.
EPS 1Y (TTM)-50.86%
EPS 3Y4.97%
EPS 5YN/A
EPS Q2Q%4500%
Revenue 1Y (TTM)31.44%
Revenue growth 3Y51.91%
Revenue growth 5YN/A
Sales Q2Q%31.01%

3.2 Future

  • PACS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.60% yearly.
  • The Revenue is expected to grow by 16.94% on average over the next years. This is quite good.
EPS Next Y32.6%
EPS Next 2Y34.18%
EPS Next 3Y26.6%
EPS Next 5YN/A
Revenue Next Year35.43%
Revenue Next 2Y20.78%
Revenue Next 3Y16.94%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PACS Yearly Revenue VS EstimatesPACS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2B 4B 6B
PACS Yearly EPS VS EstimatesPACS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0.5 1 1.5 2

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 29.46, the valuation of PACS can be described as expensive.
  • The rest of the industry has a similar Price/Earnings ratio as PACS.
  • Compared to an average S&P500 Price/Earnings ratio of 27.30, PACS is valued at the same level.
  • A Price/Forward Earnings ratio of 20.35 indicates a rather expensive valuation of PACS.
  • PACS's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. PACS is cheaper than 61.00% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of PACS to the average of the S&P500 Index (24.04), we can say PACS is valued inline with the index average.
Industry RankSector Rank
PE 29.46
Fwd PE 20.35
PACS Price Earnings VS Forward Price EarningsPACS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • PACS's Enterprise Value to EBITDA is on the same level as the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 41.39
PACS Per share dataPACS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • PACS's earnings are expected to grow with 26.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.9
PEG (5Y)N/A
EPS Next 2Y34.18%
EPS Next 3Y26.6%

More info and screens

0

5. Dividend

5.1 Amount

  • PACS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PACS GROUP INC

NYSE:PACS (1/13/2026, 8:04:00 PM)

After market: 42.91 +0.78 (+1.85%)

42.13

+0.62 (+1.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-19
Earnings (Next)N/A
Inst Owners28.43%
Inst Owner Change0.01%
Ins Owners71.03%
Ins Owner Change0.58%
Market Cap6.60B
Revenue(TTM)4.09B
Net Income(TTM)55.76M
Analysts83.33
Price Target36.89 (-12.44%)
Short Float %7.91%
Short Ratio2.11
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.99%
Min EPS beat(2)8.66%
Max EPS beat(2)13.32%
EPS beat(4)2
Avg EPS beat(4)-6.8%
Min EPS beat(4)-32.29%
Max EPS beat(4)13.32%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)13.55%
Min Revenue beat(2)13.26%
Max Revenue beat(2)13.85%
Revenue beat(4)4
Avg Revenue beat(4)13.41%
Min Revenue beat(4)13.1%
Max Revenue beat(4)13.85%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)17.62%
PT rev (3m)9.6%
EPS NQ rev (1m)2.57%
EPS NQ rev (3m)1.31%
EPS NY rev (1m)-21.32%
EPS NY rev (3m)-7.22%
Revenue NQ rev (1m)0.79%
Revenue NQ rev (3m)15.66%
Revenue NY rev (1m)0.24%
Revenue NY rev (3m)15.81%
Valuation
Industry RankSector Rank
PE 29.46
Fwd PE 20.35
P/S 1.61
P/FCF N/A
P/OCF N/A
P/B 7.57
P/tB 8.21
EV/EBITDA 41.39
EPS(TTM)1.43
EY3.39%
EPS(NY)2.07
Fwd EY4.91%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS26.11
BVpS5.56
TBVpS5.13
PEG (NY)0.9
PEG (5Y)N/A
Graham Number13.38
Profitability
Industry RankSector Rank
ROA 0.99%
ROE 6.4%
ROCE 2.78%
ROIC 1.75%
ROICexc 1.91%
ROICexgc 1.94%
OM 3.01%
PM (TTM) 1.36%
GM 19.38%
FCFM N/A
ROA(3y)3.46%
ROA(5y)N/A
ROE(3y)120.58%
ROE(5y)N/A
ROIC(3y)4.48%
ROIC(5y)N/A
ROICexc(3y)4.61%
ROICexc(5y)N/A
ROICexgc(3y)4.74%
ROICexgc(5y)N/A
ROCE(3y)7.09%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-25.04%
OM growth 5YN/A
PM growth 3Y-30.78%
PM growth 5YN/A
GM growth 3Y-5.21%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Debt/EBITDA 2.28
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.94
Quick Ratio 0.94
Altman-Z 1.68
F-ScoreN/A
WACC8.83%
ROIC/WACC0.2
Cap/Depr(3y)147.98%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.35%
Cap/Sales(5y)N/A
Profit Quality(3y)200.6%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50.86%
EPS 3Y4.97%
EPS 5YN/A
EPS Q2Q%4500%
EPS Next Y32.6%
EPS Next 2Y34.18%
EPS Next 3Y26.6%
EPS Next 5YN/A
Revenue 1Y (TTM)31.44%
Revenue growth 3Y51.91%
Revenue growth 5YN/A
Sales Q2Q%31.01%
Revenue Next Year35.43%
Revenue Next 2Y20.78%
Revenue Next 3Y16.94%
Revenue Next 5YN/A
EBIT growth 1Y-40.77%
EBIT growth 3Y13.87%
EBIT growth 5YN/A
EBIT Next Year78.74%
EBIT Next 3Y30.46%
EBIT Next 5YN/A
FCF growth 1Y1579.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y476.7%
OCF growth 3Y85.44%
OCF growth 5YN/A

PACS GROUP INC / PACS FAQ

What is the fundamental rating for PACS stock?

ChartMill assigns a fundamental rating of 3 / 10 to PACS.


What is the valuation status of PACS GROUP INC (PACS) stock?

ChartMill assigns a valuation rating of 3 / 10 to PACS GROUP INC (PACS). This can be considered as Overvalued.


What is the profitability of PACS stock?

PACS GROUP INC (PACS) has a profitability rating of 2 / 10.


What is the valuation of PACS GROUP INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for PACS GROUP INC (PACS) is 29.46 and the Price/Book (PB) ratio is 7.57.